Oxidative stress, inflammation, and vascular aging in hypertension

Hypertension

Volumn 70, Issue 4, 2017, Pages 660-667

  Guzik, Tomasz J ^a,b   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; MICRORNA; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOGENIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TRANSCRIPTION FACTOR MSX2; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR RUNX2; VASCULAR CELL ADHESION MOLECULE 1;

AGING; ARTICLE; BLOOD VESSEL CALCIFICATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK FACTOR; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BLOOD VESSEL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGING; ANIMALS; BLOOD VESSELS; HUMANS; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS;

EID: 85030998179     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.117.07802     Document Type: Article

References (102)

1. Sun Z. Aging, arterial stiffness, and hypertension. Hypertension. 2015;65:252-256. doi: 10.1161/HYPERTENSIONAHA.114.03617.
2. Cunha PG, Boutouyrie P, Nilsson PM, Laurent S. Early vascular ageing (EVA): definitions and clinical applicability [published online ahead of print April 12, 2017]. Curr Hypertens Rev. doi: 10.2174/1573402113666 170413094319.
3. Wilk G, Osmenda G, Matusik P, Nowakowski D, Jasiewicz-Honkisz B, Ignacak A, Czesnikiewicz-Guzik M, Guzik TJ. Endothelial function assessment in atherosclerosis: comparison of brachial artery flow-mediated vasodilation and peripheral arterial tonometry. Pol Arch Med Wewn. 2013;123:443-452.
4. Duca L, Blaise S, Romier B, Laffargue M, Gayral S, El Btaouri H, Kawecki C, Guillot A, Martiny L, Debelle L, Maurice P. Matrix ageing and vascular impacts: focus on elastin fragmentation. Cardiovasc Res. 2016;110:298-308. doi: 10.1093/cvr/cvw061.
5. Cannata A, Camparini L, Sinagra G, Giacca M, Loffredo FS. Pathways for salvage and protection of the heart under stress: novel routes for cardiac rejuvenation. Cardiovasc Res. 2016;111:142-153. doi: 10.1093/cvr/cvw106.
6. Kovacic JC, Moreno P, Hachinski V, Nabel EG, Fuster V. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. Circulation. 2011;123:1650-1660. doi: 10.1161/CIRCULATIONAHA.110.007021.
7. Perk J, De Backer G, Gohlke H, et al; Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice; European Association for Cardiovascular Prevention and Rehabilitation. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis. 2012;223:1-68. doi: 10.1016/j.atherosclerosis.2012.05.007.
8. Lakatta EG. Central arterial aging and the epidemic of systolic hypertension and atherosclerosis. J Am Soc Hypertens. 2007;1:302-340. doi: 10.1016/j.jash.2007.05.001.
9. Nilsson PM, Lurbe E, Laurent S. The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. J Hypertens. 2008;26:1049-1057. doi: 10.1097/HJH.0b013e3282f82c3e.
10. Nilsson PM, Boutouyrie P, Laurent S. Vascular aging: a tale of EVA and ADAM in cardiovascular risk assessment and prevention. Hypertension. 2009;54:3-10. doi: 10.1161/HYPERTENSIONAHA.109.129114.
11. Tchalla AE, Wellenius GA, Travison TG, Gagnon M, Iloputaife I, Dantoine T, Sorond FA, Lipsitz LA. Circulating vascular cell adhesion molecule-1 is associated with cerebral blood flow dysregulation, mobility impairment, and falls in older adults. Hypertension. 2015;66:340-346. doi: 10.1161/HYPERTENSIONAHA.115.05180.
12. Dumurgier J, Elbaz A. Gait decline: the role of cerebral small vessel disease and biomarkers. Hypertension. 2015;66:263-264. doi: 10.1161/HYPERTENSIONAHA.115.05437.
13. Guzik TJ, Skiba D, Touyz RM, Harrison DG. The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovasc Res. 2017;113:1009-1023. doi:10.1093/cvr/cvx108.
14. Sehgel NL, Sun Z, Hong Z, Hunter WC, Hill MA, Vatner DE, Vatner SF, Meininger GA. Augmented vascular smooth muscle cell stiffness and adhesion when hypertension is superimposed on aging. Hypertension. 2015;65:370-377. doi: 10.1161/HYPERTENSIONAHA.114.04456.
15. Wirth A, Wang S, Takefuji M, Tang C, Althoff TF, Schweda F, Wettschureck N, Offermanns S. Age-dependent blood pressure elevation is due to increased vascular smooth muscle tone mediated by G-protein signalling. Cardiovasc Res. 2016;109:131-140. doi: 10.1093/cvr/cvv249.
16. Yung LM, Sanchez-Duffhues G, Ten Dijke P, Yu PB. Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells. Cardiovasc Res. 2015;108:278-287. doi: 10.1093/cvr/cvv221.
17. Nosalski R, Guzik TJ. Perivascular adipose tissue inflammation in vascular disease [published online ahead of print February 9, 2017]. Br J Pharmacol. doi: 10.1111/bph.13705. http://onlinelibrary.wiley.com/doi/10.1111/bph.13705/full.
18. Merino D, Villar AV, Garcia R, Tramullas M, Ruiz L, Ribas C, Cabezudo S, Nistal JF, Hurle MA. BMP-7 attenuates left ventricular remodelling under pressure overload and facilitates reverse remodelling and functional recovery. Cardiovasc Res. 2016;110:331-345. doi: 10.1093/cvr/cvw076.
19. Bruno RM, Duranti E, Ippolito C, Segnani C, Bernardini N, Di Candio G, Chiarugi M, Taddei S, Virdis A. Different impact of essential hypertension on structural and functional age-related vascular changes. Hypertension. 2017;69:71-78. doi: 10.1161/HYPERTENSIONAHA.116.08041.
20. Meijles DN, Pagano PJ. Nox and inflammation in the vascular adventitia. Hypertension. 2016;67:14-19. doi: 10.1161/HYPERTENSIONAHA. 115.03622.
21. Wu J, Saleh MA, Kirabo A, et al. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest. 2016;126:1607. doi: 10.1172/JCI87425.
22. Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol. 2012;56:216-231. doi: 10.1016/j.vph.2012.02.012.
23. Takayanagi T, Kawai T, Forrester SJ, Obama T, Tsuji T, Fukuda Y, Elliott KJ, Tilley DG, Davisson RL, Park JY, Eguchi S. Role of epidermal growth factor receptor and endoplasmic reticulum stress in vascular remodeling induced by angiotensin II. Hypertension. 2015;65:1349-1355. doi: 10.1161/HYPERTENSIONAHA.115.05344.
24. Minami T, Satoh K, Nogi M, Kudo S, Miyata S, Tanaka S, Shimokawa H. Statins up-regulate SmgGDS through ß1-integrin/Akt1 pathway in endothelial cells. Cardiovasc Res. 2016;109:151-161. doi: 10.1093/cvr/cvv253.
25. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension. 2009;54:388-392. doi: 10.1161/HYPERTENSIONAHA.109.133116.
26. Laurent S, Boutouyrie P. The structural factor of hypertension: large and small artery alterations. Circ Res. 2015;116:1007-1021. doi: 10.1161/CIRCRESAHA.116.303596.
27. Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal. 2013;19:1110-1120. doi: 10.1089/ars.2012.4641.
28. Montezano AC, Burger D, Ceravolo GS, Yusuf H, Montero M, Touyz RM. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clin Sci (Lond). 2011;120:131-141. doi: 10.1042/CS20100384.
29. Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik TJ. NADPH oxidases in vascular pathology. Antioxid Redox Signal. 2014;20:2794-2814. doi: 10.1089/ars.2013.5607.
30. Schroder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, Brandes RP. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res. 2012;110:1217-1225. doi: 10.1161/CIRCRESAHA.112.267054.
31. Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, Shah AM. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA. 2010;107:18121-18126. doi: 10.1073/pnas.1009700107.
32. Guzik TJ, Griendling KK. NADPH oxidases: molecular understanding finally reaching the clinical level? Antioxid Redox Signal. 2009;11:2365-2370. doi: 10.1089/ars.2009.2615.
33. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, Touyz RM. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of type 2 diabetes. Clin Sci (Lond). 2013;124:191-202. doi: 10.1042/CS20120330.
34. Neves KB, Nguyen Dinh Cat A, Lopes RA, Rios FJ, Anagnostopoulou A, Lobato NS, de Oliveira AM, Tostes RC, Montezano AC, Touyz RM. Chemerin regulates crosstalk between adipocytes and vascular cells through Nox. Hypertension. 2015;66:657-666. doi: 10.1161/HYPERTENSIONAHA.115.05616.
35. Alesutan I, Feger M, Tuffaha R, et al. Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine. Cardiovasc Res. 2016;110:408-418. doi: 10.1093/cvr/cvw062.
36. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest. 1992;90:1116-1121. doi: 10.1172/JCI115929.
37. Gao X, Yang T, Liu M, Peleli M, Zollbrecht C, Weitzberg E, Lundberg JO, Persson AE, Carlstrom M. NADPH oxidase in the renal microvasculature is a primary target for blood pressure-lowering effects by inorganic nitrate and nitrite. Hypertension. 2015;65:161-170. doi: 10.1161/HYPERTENSIONAHA.114.04222.
38. Alves-Lopes R, Neves KB, Montezano AC, Harvey A, Carneiro FS, Touyz RM, Tostes RC. Internal pudental artery dysfunction in diabetes mellitus is mediated by NOX1-Derived ROS-, Nrf2-, and rho kinasedependent mechanisms. Hypertension. 2016;68:1056-1064. doi: 10.1161/HYPERTENSIONAHA.116.07518.
39. Lopes RA, Neves KB, Tostes RC, Montezano AC, Touyz RM. Downregulation of nuclear factor erythroid 2-related factor and associated antioxidant genes contributes to redox-sensitive vascular dysfunction in hypertension. Hypertension. 2015;66:1240-1250. doi: 10.1161/HYPERTENSIONAHA.115.06163.
40. Touyz RM, Montezano AC. Vascular Nox4: a multifarious NADPH oxidase. Circ Res. 2012;110:1159-1161. doi: 10.1161/CIRCRESAHA. 112.269068.
41. Schurmann C, Rezende F, Kruse C, Yasar Y, Lowe O, Fork C, van de Sluis B, Bremer R, Weissmann N, Shah AM, Jo H, Brandes RP, Schroder K. The NADPH oxidase Nox4 has anti-atherosclerotic functions. Eur Heart J. 2015;36:3447-3456. doi: 10.1093/eurheartj/ehv460.
42. Przybylska D, Janiszewska D, Gozdzik A, Bielak-Zmijewska A, Sunderland P, Sikora E, Mosieniak G. NOX4 downregulation leads to senescence of human vascular smooth muscle cells. Oncotarget. 2016;7:66429-66443. doi: 10.18632/oncotarget.12079.
43. Smyrnias I, Zhang X, Zhang M, Murray TV, Brandes RP, Schroder K, Brewer AC, Shah AM. Nicotinamide adenine dinucleotide phosphate oxidase-4-dependent upregulation of nuclear factor erythroid-derived 2-like 2 protects the heart during chronic pressure overload. Hypertension. 2015;65:547-553. doi: 10.1161/HYPERTENSIONAHA.114.04208.
44. Cowley AW Jr, Yang C, Zheleznova NN, Staruschenko A, Kurth T, Rein L, Kumar V, Sadovnikov K, Dayton A, Hoffman M, Ryan RP, Skelton MM, Salehpour F, Ranji M, Geurts A. Evidence of the importance of Nox4 in production of hypertension in Dahl salt-sensitive rats. Hypertension. 2016;67:440-450. doi: 10.1161/HYPERTENSIONAHA.115.06280.
45. Kriegel AJ, Baker MA, Liu Y, Liu P, Cowley AW Jr, Liang M. Endogenous microRNAs in human microvascular endothelial cells regulate mRNAs encoded by hypertension-related genes. Hypertension. 2015;66:793-799. doi: 10.1161/HYPERTENSIONAHA.115.05645.
46. Kyrychenko S, Kyrychenko V, Badr MA, Ikeda Y, Sadoshima J, Shirokova N. Pivotal role of miR-448 in the development of ROS-induced cardiomyopathy. Cardiovasc Res. 2015;108:324-334. doi: 10.1093/cvr/cvv238.
47. Hoefer IE, Steffens S, Ala-Korpela M, et al; ESC Working Group Atherosclerosis and Vascular Biology. Novel methodologies for biomarker discovery in atherosclerosis. Eur Heart J. 2015;36:2635-2642. doi: 10.1093/eurheartj/ehv236.
48. Vacca M, Di Eusanio M, Cariello M, et al. Integrative miRNA and wholegenome analyses of epicardial adipose tissue in patients with coronary atherosclerosis. Cardiovasc Res. 2016;109:228-239. doi: 10.1093/cvr/cvv266.
49. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488-496. doi: 10.1161/CIRCRESAHA.107.162800.
50. Itani HA, Dikalova AE, McMaster WG, Nazarewicz RR, Bikineyeva AT, Harrison DG, Dikalov SI. Mitochondrial cyclophilin D in vascular oxidative stress and hypertension. Hypertension. 2016;67:1218-1227. doi: 10.1161/HYPERTENSIONAHA.115.07085.
51. Song CY, Ghafoor K, Ghafoor HU, Khan NS, Thirunavukkarasu S, Jennings BL, Estes AM, Zaidi S, Bridges D, Tso P, Gonzalez FJ, Malik KU. Cytochrome P450 1B1 contributes to the development of atherosclerosis and hypertension in apolipoprotein E-deficient mice. Hypertension. 2016;67:206-213. doi: 10.1161/HYPERTENSIONAHA. 115.06427.
52. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209. doi: 10.1172/JCI14172.
53. Kossmann S, Hu H, Steven S, et al. Inflammatory monocytes determine endothelial nitric-oxide synthase uncoupling and nitro-oxidative stress induced by angiotensin II. J Biol Chem. 2014;289:27540-27550. doi: 10.1074/jbc.M114.604231.
54. Guzik TJ, Olszanecki R, Sadowski J, Kapelak B, Rudzinski P, Jopek A, Kawczynska A, Ryszawa N, Loster J, Jawien J, Czesnikiewicz-Guzik M, Channon KM, Korbut R. Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. J Physiol Pharmacol. 2005;56:313-323.
55. Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M, Villarroya F. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res. 2015;106:19-31. doi: 10.1093/cvr/cvu263.
56. Carey RM. Resistant hypertension: mineralocorticoid receptor antagonist or renal denervation? Hypertension. 2016;67:278-280. doi: 10.1161/HYPERTENSIONAHA.115.06616.
57. Arnold AC, Okamoto LE, Gamboa A, Black BK, Raj SR, Elijovich F, Robertson D, Shibao CA, Biaggioni I. Mineralocorticoid receptor activation contributes to the supine hypertension of autonomic failure. Hypertension. 2016;67:424-429. doi: 10.1161/HYPERTENSIONAHA.115.06617.
58. Ayuzawa N, Nagase M, Ueda K, Nishimoto M, Kawarazaki W, Marumo T, Aiba A, Sakurai T, Shindo T, Fujita T. Rac1-mediated activation of mineralocorticoid receptor in pressure overload-induced cardiac injury. Hypertension. 2016;67:99-106. doi: 10.1161/HYPERTENSIONAHA. 115.06054.
59. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-263. doi: 10.1161/HYPERTENSIONAHA. 114.04488.
60. Bender SB, DeMarco VG, Padilla J, Jenkins NT, Habibi J, Garro M, Pulakat L, Aroor AR, Jaffe IZ, Sowers JR. Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension. 2015;65:1082-1088. doi: 10.1161/HYPERTENSIONAHA. 114.04912.
61. Jia G, Habibi J, DeMarco VG, Martinez-Lemus LA, Ma L, Whaley-Connell AT, Aroor AR, Domeier TL, Zhu Y, Meininger GA, Barrett Mueller K, Jaffe IZ, Sowers JR. Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension. 2015;66:1159-1167. doi: 10.1161/HYPERTENSIONAHA.115.06015.
62. Briet M, Barhoumi T, Mian MO, Coelho SC, Ouerd S, Rautureau Y, Coffman TM, Paradis P, Schiffrin EL. Aldosterone-induced vascular remodeling and endothelial dysfunction require functional angiotensin type 1a receptors. Hypertension. 2016;67:897-905. doi: 10.1161/HYPERTENSIONAHA.115.07074.
63. Huby AC, Otvos L Jr, Belin de Chantemele EJ. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension. 2016;67:1020-1028. doi: 10.1161/HYPERTENSIONAHA.115.06642.
64. Lother A, Furst D, Bergemann S, Gilsbach R, Grahammer F, Huber TB, Hilgendorf I, Bode C, Moser M, Hein L. Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension. 2016;67:130-138. doi: 10.1161/HYPERTENSIONAHA.115.06530.
65. Lother A, Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease. Hypertension. 2016;68:6-10. doi: 10.1161/HYPERTENSIONAHA.116.07418.
66. DeMarco VG, Habibi J, Jia G, Aroor AR, Ramirez-Perez FI, Martinez-Lemus LA, Bender SB, Garro M, Hayden MR, Sun Z, Meininger GA, Manrique C, Whaley-Connell A, Sowers JR. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension. 2015;66:99-107. doi: 10.1161/HYPERTENSIONAHA.115.05674.
67. Urbanski K, Ludew D, Filip G, Filip M, Sagan A, Szczepaniak P, Grudzien G, Sadowski J, Jasiewicz-Honkisz B, Sliwa T, Kapelak B, McGinnigle E, Mikolajczyk T, Guzik T. CD14+CD16++ "nonclassical" monocytes are associated with endothelial dysfunction in patients with coronary artery disease. Thromb Hemost. 2017;117:971-980. doi: 10.1160/TH16-08-0614.
68. Nosalski R, McGinnigle E, Siedlinski M, Guzik TJ. Novel immune mechanisms in hypertension and cardiovascular risk. Curr Cardiovasc Risk Rep. 2017;11:12. doi: 10.1007/s12170-017-0537-6.
69. Januszewicz A, Guzik T, Prejbisz A, Mikolajczyk T, Osmenda G, Januszewicz W. Malignant hypertension: new aspects of an old clinical entity. Pol Arch Med Wewn. 2016;126:86-93.
70. Guzik TJ, Mikolajczyk T. In search of the T cell involved in hypertension and target organ damage. Hypertension. 2014;64:224-226. doi: 10.1161/HYPERTENSIONAHA.114.03340.
71. Mikolajczyk TP, Nosalski R, Szczepaniak P, et al. Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension. FASEB J. 2016;30:1987-1999. doi: 10.1096/fj.201500088R.
72. McEver RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107:331-339. doi: 10.1093/cvr/cvv154.
73. Scheiermann C, Frenette PS, Hidalgo A. Regulation of leucocyte homeostasis in the circulation. Cardiovasc Res. 2015;107:340-351. doi: 10.1093/cvr/cvv099.
74. Czesnikiewicz-Guzik M, Lee WW, Cui D, Hiruma Y, Lamar DL, Yang ZZ, Ouslander JG, Weyand CM, Goronzy JJ. T cell subset-specific susceptibility to aging. Clin Immunol. 2008;127:107-118. doi: 10.1016/j. clim.2007.12.002.
75. Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, Chang DY, Choi YS, Lee SH, Kang SM, Jang Y, Yoo OJ, Shin EC, Park S. Immunosenescent CD8+ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013;62:126-133. doi: 10.1161/HYPERTENSIONAHA.113.00689.
76. Itani HA, McMaster WG Jr, Saleh MA, et al. Activation of human T cells in hypertension: studies of humanized mice and hypertensive humans. Hypertension. 2016;68:123-132. doi: 10.1161/HYPERTENSIONAHA. 116.07237.
77. Yodoi K, Yamashita T, Sasaki N, Kasahara K, Emoto T, Matsumoto T, Kita T, Sasaki Y, Mizoguchi T, Sparwasser T, Hirata K. Foxp3+ regulatory T cells play a protective role in angiotensin II-induced aortic aneurysm formation in mice. Hypertension. 2015;65:889-895. doi: 10.1161/HYPERTENSIONAHA.114.04934.
78. Chan CT, Sobey CG, Lieu M, et al. Obligatory Role for B Cells in the development of angiotensin II-dependent hypertension. Hypertension. 2015;66:1023-1033. doi: 10.1161/HYPERTENSIONAHA.115.05779.
79. Sundgren NC, Vongpatanasin W, Boggan BM, Tanigaki K, Yuhanna IS, Chambliss KL, Mineo C, Shaul PW. IgG receptor Fc?RIIB plays a key role in obesity-induced hypertension. Hypertension. 2015;65:456-462. doi: 10.1161/HYPERTENSIONAHA.114.04670.
80. Tay C, Liu YH, Hosseini H, Kanellakis P, Cao A, Peter K, Tipping P, Bobik A, Toh BH, Kyaw T. B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation. Cardiovasc Res. 2016;111:385-397. doi: 10.1093/cvr/cvw186.
81. Weber C, Shantsila E, Hristov M, Caligiuri G, Guzik T, Heine GH, Hoefer IE, Monaco C, Peter K, Rainger E, Siegbahn A, Steffens S, Wojta J, Lip GY. Role and analysis of monocyte subsets in cardiovascular disease. Joint consensus document of the European Society of Cardiology (ESC) working groups "atherosclerosis & vascular biology" and "thrombosis". Thromb Haemost. 2016;116:626-637. doi: 10.1160/TH16-02-0091.
82. Gerhardt T, Ley K. Monocyte trafficking across the vessel wall. Cardiovasc Res. 2015;107:321-330. doi: 10.1093/cvr/cvv147.
83. Moore JP, Vinh A, Tuck KL, Sakkal S, Krishnan SM, Chan CT, Lieu M, Samuel CS, Diep H, Kemp-Harper BK, Tare M, Ricardo SD, Guzik TJ, Sobey CG, Drummond GR. M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure. Am J Physiol Heart Circ Physiol. 2015;309:H906-H917. doi: 10.1152/ajpheart.00821.2014.
84. Skiba DS, Nosalski R, Mikolajczyk TP, Siedlinski M, Rios FJ, Montezano AC, Jawien J, Olszanecki R, Korbut R, Czesnikiewicz-Guzik M, Touyz RM, Guzik TJ. Antiatherosclerotic effect of ang-(1-7) non-peptide mimetic (AVE 0991) is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. Br J Pharmacol. 2017. doi: 10.1111/bph.13685.
85. Madrigal-Matute J, Fernandez-Laso V, Sastre C, Llamas-Granda P, Egido J, Martin-Ventura JL, Zalba G, Blanco-Colio LM. TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovasc Res. 2015;108:139-147. doi: 10.1093/cvr/cvv204.
86. Harrison DG, Guzik TJ. Macrophages come to mind as keys to cognitive decline. J Clin Invest. 2016;126:4393-4395. doi: 10.1172/JCI91277.
87. Kirabo A, Fontana V, de Faria AP, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124:4642-4656. doi: 10.1172/JCI74084.
88. Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP. The interplay between angiotensin II, TLR4 and hypertension. Pharmacol Res. 2017;120:88-96. doi: 10.1016/j.phrs.2017.03.017.
89. Echavarria R, Mayaki D, Neel JC, Harel S, Sanchez V, Hussain SN. Angiopoietin-1 inhibits toll-like receptor 4 signalling in cultured endothelial cells: role of miR-146b-5p. Cardiovasc Res. 2015;106:465-477. doi: 10.1093/cvr/cvv120.
90. Jiang Y, Lu L, Hu Y, Li Q, An C, Yu X, Shu L, Chen A, Niu C, Zhou L, Yang Z. Resistin induces hypertension and insulin resistance in mice via a TLR4-dependent pathway. Sci Rep. 2016;6:22193. doi: 10.1038/srep22193.
91. Singh MV, Cicha MZ, Meyerholz DK, Chapleau MW, Abboud FM. Dual activation of TRIF and MyD88 adaptor proteins by angiotensin II evokes opposing effects on pressure, cardiac hypertrophy, and inflammatory gene expression. Hypertension. 2015;66:647-656. doi: 10.1161/HYPERTENSIONAHA.115.06011.
92. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, Kamel H, Knopman DS, Launer LJ, Saczynski JS, Seshadri S, Zeki Al Hazzouri A; American Heart Association Council on Hypertension; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68:e67-e94. doi: 10.1161/HYP.0000000000000053.
93. Cifuentes D, Poittevin M, Dere E, Broqueres-You D, Bonnin P, Benessiano J, Pocard M, Mariani J, Kubis N, Merkulova-Rainon T, Levy BI. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension. 2015;65:218-224. doi: 10.1161/HYPERTENSIONAHA.114.04139.
94. Hao Y, Tsuruda T, Sekita-Hatakeyama Y, Kurogi S, Kubo K, Sakamoto S, Nakamura M, Udagawa N, Sekimoto T, Hatakeyama K, Chosa E, Asada Y, Kitamura K. Cardiac hypertrophy is exacerbated in aged mice lacking the osteoprotegerin gene. Cardiovasc Res. 2016;110:62-72. doi: 10.1093/cvr/cvw025.
95. Siedlinski M, Nosalski R, Szczepaniak P, Ludwig-Galezowska AH, Mikolajczyk T, Filip M, Osmenda G, Wilk G, Nowak M, Wolkow P, Guzik TJ. Vascular transcriptome profiling identifies sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction. Sci Rep. 2017;7:44131. doi: 10.1038/srep44131.
96. Wang M, Kim SH, Monticone RE, Lakatta EG. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension. 2015;65:698-703. doi: 10.1161/HYPERTENSIONAHA.114.03618.
97. Di Gregoli K, George SJ, Jackson CL, Newby AC, Johnson JL. Differential effects of tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 on atherosclerosis and monocyte/macrophage invasion. Cardiovasc Res. 2016;109:318-330. doi: 10.1093/cvr/cvv268.
98. Ma Y, Chiao YA, Clark R, Flynn ER, Yabluchanskiy A, Ghasemi O, Zouein F, Lindsey ML, Jin YF. Deriving a cardiac ageing signature to reveal MMP-9-dependent inflammatory signalling in senescence. Cardiovasc Res. 2015;106:421-431. doi: 10.1093/cvr/cvv128.
99. Orriols M, Varona S, Marti-Pamies I, Galan M, Guadall A, Escudero JR, Martin-Ventura JL, Camacho M, Vila L, Martinez-Gonzalez J, Rodriguez C. Down-regulation of Fibulin-5 is associated with aortic dilation: role of inflammation and epigenetics. Cardiovasc Res. 2016;110:431-442. doi: 10.1093/cvr/cvw082.
100. Liu Y, Wang Y, Shi H, Jia L, Cheng J, Cui W, Li H, Li P, Du J. CARD9 mediates necrotic smooth muscle cell-induced inflammation in macrophages contributing to neointima formation of vein grafts. Cardiovasc Res. 2015;108:148-158. doi: 10.1093/cvr/cvv211.
101. Passacquale G, Di Giosia P, Ferro A. The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials. Cardiovasc Res. 2016;109:9-23. doi: 10.1093/cvr/cvv227.
102. Lewis DR, Petersen LK, York AW, Ahuja S, Chae H, Joseph LB, Rahimi S, Uhrich KE, Haser PB, Moghe PV. Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques. Cardiovasc Res. 2016;109:283-293. doi: 10.1093/cvr/cvv237.